The development of blood has long served as a model for mammalian cell type specification and differentiation, and yet the underlying transcriptional networks remain ill defined. Characterisation of such networks will require genome-wide identification of cis-regulatory sequences and an understanding of how regulatory information is encoded in the primary DNA sequence. Despite progress in lower organisms, genome-wide computational identification of mammalian cisregulatory sequences has been hindered by increased genomic complexity and cumbersome transgenic assays. Starting with a well-characterised blood stem cell enhancer from the SCL gene, we have developed computational tools for the identification of functionally related gene regulatory sequences. Two candidate enhancers discovered in this way were located in intron 1 of the Fli-1 and PRH/Hex genes, both transcription factors previously implicated in controlling blood and endothelial development. Subsequent transgenic and biochemical analysis demonstrated that the two computationally identified enhancers are functionally related to the SCL stem cell enhancer. The approach developed here may therefore be useful for identifying additional enhancers involved in the control of early blood and endothelial development, and may be adapted to decipher transcriptional regulatory codes controlling a broad range of mammalian developmental programmes.
Introduction
A major challenge of the post-genome era will be the integration of genomic sequences with transcription factor function and expression to decipher the gene regulatory networks which lie at the heart of development (1, 2) . Progress towards this goal will require identification of gene regulatory regions within the genomic landscape and an understanding of the way in which specific patterns of expression are encoded within the primary DNA sequence. In silico approaches, which identify gene regulatory regions with specific biological activity, are proving increasingly successful in "lower" organisms such as yeast or flies (3) (4) (5) (6) (7) . However, the higher biological complexity of mammals is associated with increasingly intricate mechanisms of gene regulation (2) , and genome-wide identification of mammalian regulatory regions with predicted biological activity demonstrated through in vivo transgenic analysis has not been described.
Haematopoiesis has long served as a paradigm for adult stem cell systems and markers are available for mature progeny of all haematopoietic lineages as well as for a plethora of progenitors with varying potentials. Studies over the last 20 years have established that transcriptional control is central to the specification and subsequent differentiation of haematopoietic stem cells (HSCs) (8, 9) . With many of the key transcription factors known, haematopoiesis provides a powerful cellular system for the analysis of mammalian gene regulatory networks. The key missing ingredient, particularly for the stem and progenitor cell stages, is a set of experimentally validated gene regulatory regions together with a molecular understanding of their biological activity.
Here we describe new computational tools for the identification of mammalian enhancers based on evolutionarily conserved patterns of transcription factor binding sites. Starting with a wellcharacterised blood stem cell enhancer, we demonstrate that this approach permits identification of enhancers with predicted biological activity in vitro and in vivo. Moreover, molecular and transgenic analysis of these new enhancers allowed us to develop a nascent transcription factor network controlling formation of early blood and endothelium. The approach presented here is therefore likely to allow characterisation of transcriptional regulatory codes controlling a broad range of mammalian developmental programmes.
Results
In order to identify transcriptional control regions active during early embryonic haematopoietic development, we have developed a strategy that is based upon a haematopoietic stem cell enhancer (+19 enhancer) identified downstream of the SCL transcription factor, a key regulator of haematopoietic stem cell formation (10) . Transgenic reporter studies have demonstrated that the SCL +19 element (numbering of enhancers refers to the distance in kb from the transcriptional start site) targets expression to haemangioblasts, haematopoietic stem cells and endothelium (11) (12) (13) . Subsequent molecular analysis identified two conserved Ets sites and one conserved GATA site ( Figure 1A ) all of which were critical for enhancer activity (13) . We now developed a new suite of bioinformatic analysis tools to generate human genome-wide catalogues of potential transcription factor binding sites. The human genome contains over 47 million potential Ets binding sites (GGAA/T) and over 18 million GATA binding sites (GATA). In order to identify the subset of sites likely to be functional, we excluded motifs located in repetitive DNA and included only those for which the core motif was conserved in whole genome alignments of human, mouse and rat, and was located within an 8bp block of sequence identity. The latter criterion was based on our previous comparative analysis of multiple mammalian SCL loci, which demonstrated that functionally significant binding sites are typically situated in blocks of extended sequence identity (14) . These approaches reduced the number of sites to approximately 625,000 Ets and 189,000
GATA sites (Figure 1 B) .
To further enrich for putative regulatory elements with sequence properties similar to those of the SCL +19 enhancer, we developed a new program (TFBScluster) and used it to determine the locations of binding site clusters reflecting the combination of sites found in the SCL +19 core enhancer (at least two conserved Ets sites and at least one conserved GATA site within a 50 bp sequence window). Clusters found in coding exons or further than 100 kb away from the first or last exons of the nearest Swissprot (15) Enhancer activity is frequently dependent on the precise spacing and orientation of its constituent binding sites, and an understanding of these constraints can help in silico identification of bona fide transcriptional control regions (7) . The SCL +19 enhancer contains two Ets sites and one GATA site, all in the forward orientation and separated by between 1.5 to 2.5 turns (17-24 bp) of the double helix in all four mammalian species studied ( Figure 1A ). Previous studies have demonstrated that this spatial arrangement of the constituent binding sites is critical for enhancer activity (13) . We therefore extracted only those clusters with a spatial organisation similar to the SCL +19 enhancer (two Ets followed by one GATA site, all in the forward orientation and each separated by 1 to 3 turns of the double helix). This resulted in the identification of 67 clusters, which were localised to 64 genes ( Figure 1B ; for localisation procedure see Materials and Methods section and supplementary data at http://hscl.cimr.cam.ac.uk/supplementary_donaldson04.html).
These 64 genes included the blood stem cell marker CD34 as well as several other membrane receptors expressed during early blood and endothelial development. Interestingly, the gene list contained 18 transcription factors suggesting that the above strategy may be able to identify those cis regulatory sequences that constitute the nodes of transcription factor networks. Two of the 18 transcription factors encoding the Fli-1 and PRH (also known as Hex) genes had been linked with blood formation, although their position within a regulatory hierarchy remained ill defined (13, (18) (19) (20) . Comparative genomic sequence analysis demonstrated that both the Fli-1 and PRH loci contain multiple non-coding peaks of elevated sequence identity (non-coding homology peaks) ( Figure 2 ). Indeed, the region of the Fli-1 locus shown in Figure 2 contains more than 60 peaks of homology, all of which are conserved to the same degree as Fli-1 coding exons. However, only the peak situated 12 kb downstream of the start of exon 1 (Fli-1 +12 element) contained an Ets/Ets/GATA cluster similar to the SCL +19 enhancer. Similarly within the PRH locus, only the peak situated in intron 1 (PRH +1 element) contained an analogous Ets/Ets/GATA cluster. The sequence of both the Fli-1 +12 and PRH +1 regions was highly conserved in human/mouse/rat alignments, and revealed the presence of several conserved Ets and GATA sites (Fig 2, blue shading) in addition to the Ets/Ets/GATA clusters (Fig 2, yellow shading) .
In order to assess enhancer activity of the Fli-1 +12 and PRH +1 homology peaks, 500 and 600 bp fragments were subcloned into luciferase reporter constructs the activity of which was analysed following stable transfection into haematopoietic cell lines. A 604 bp fragment of the SCL +19 enhancer increased mean luciferase activity 21 fold in a multipotent progenitor cell line (416B), but was inactive in the T-cell line BW5147. Similarly, mean luciferase activity in 416B cells was increased 64 fold and 27 fold by the Fli-1 +12 and PRH +1 elements, while both were inactive in BW5147 T-cells ( Figure 3A) . Importantly, deletion of the Ets/Ets/GATA cluster from the enhancer fragment abrogated enhancer activity in 416B cells. Taken together, these data demonstrated that genome-wide computational analysis had identified functional enhancers with predictable biological activity in vitro.
In order to compare the biological activity of the Fli-1 +12, PRH +1 and SCL +19 enhancers in vivo, we generated transgenic mice carrying a lacZ reporter transgene driven by the SV40 minimal promoter and the respective enhancers. As previously described, the SV40 promoter alone does not give rise to any consistent pattern of β galactosidase expression (21) , whereas the SCL +19 enhancer directed expression to a subset of haematopoietic cells in E11.5 fetal liver as well as to endothelium and endocardium (Fig 3B; (13) ). Two out of three transgenic lines carrying the Fli-1 enhancer construct displayed strong expression of the lacZ reporter during embryonic development ( Figure 3B ). Wholemount analysis of E11.5 embryos revealed staining in the vasculature, the heart and also the fetal liver, the latter being the major haematopoietic organ at this stage of development. Histological sections demonstrated β galactosidase expression in a minority of haematopoietic cells in fetal liver, in the endocardium and in endothelium (Fig 3B and data not shown). The PRH +1 enhancer gave rise to β galactosidase expression, detectable by wholemount analysis, in the fetal liver and heart at E11.5 in four of five embryos showing β galactosidase expression (Fig 3B) . In addition to the liver and heart staining, variable ectopic expression in the brain and spinal cord was also observed in two of these embryos indicating that the PRH fragment may be susceptible to position effects. Histological sections demonstrated β galactosidase expression in a subset of fetal liver haematopoietic cells, in the endocardium and in rare endothelial cells in all four embryos with fetal liver and heart staining ( Fig 3B and data not shown).
The expression domains of both Fli-1 and PRH include developing endothelium and a subset of blood cells, including haematopoietic progenitors (22, 23) . Moreover, the PRH+1 enhancer identified in this study lies within a larger 3000 bp fragment shown previously to direct expression to yolk sac blood islands in E7.5 mouse embryos (23) . The Fli-1 +12 and PRH +1 enhancers therefore target expression to a subdomain of the normal expression pattern of their corresponding genes. Of particular note, our results demonstrate that both enhancers give rise to a pattern of tissue specific expression very similar to that generated by the SCL +19 enhancer. The genomewide strategy described here has therefore resulted in the identification of enhancers with overlapping activity in vivo. With the exception of the one GATA and two Ets sites, the sequences of the SCL +19, Fli-1 +12 and PRH +1 enhancers showed little overall similarity (see supplementary data http://hscl.cimr.cam.ac.uk/supplementary_don04.html) emphasizing the necessity to use motif-based tools rather than sequence homology searches for the computational identification of gene regulatory regions with predicted biological activity.
In order to integrate the new Fli-1 and PRH enhancers into the regulatory network controlling blood formation, it was important to identify transcription factors which bind the enhancers in vivo. Previous studies have shown that the SCL +19 enhancer is bound by GATA-2 and by the Ets factors Fli-1 and Elf-1 (13) . Chromatin immunoprecipitation experiments were therefore performed using 416B cells to identify transcription factors binding to the Fli-1 +12 and PRH +1 enhancers in vivo. The Fli-1 +12 enhancer was enriched in immunoprecipitates generated by Elf-1, Fli-1 and GATA-2 antibodies, demonstrating that this enhancer was occupied by all three factors.
The PRH +1 enhancer was enriched in immunoprecipitates generated using Fli-1 and GATA-2 antibodies with a more modest enrichment obtained with an Elf-1 antibody ( Figure 4A ). These results therefore place the two new enhancers into the same regulatory network as the SCL +19 enhancer, and have allowed us to assemble a nascent transcriptional network for early embryonic blood and endothelial development (Fig 4B) .
Discussion
The data presented in this study demonstrate the utility of a genome-wide computational approach for the identification of cis-regulatory elements with defined biological activity. This is a task of considerable magnitude given the size of the human genome and the complexity of transcriptional regulation in mammals (2) . Including introns and flanking sequences 50 kb either side of the gene, the Fli-1 locus alone contains in excess of 90 human/mouse/rat non-coding homology peaks, all of which represent candidate regulatory elements based on their level of sequence conservation (as high or higher than Fli-1 coding exons) and at least some of these are likely to play a role in the overall regulation of Fli-1 expression. Nevertheless, the current study allowed us to rapidly home in on individual homology peaks, which, through subsequent molecular and transgenic analysis, were integrated into an endothelial/blood stem-progenitor transcriptional network, with nine experimentally verified direct interactions including for example a previously unrecognised positive feedback loop involving Fli-1. The two candidate enhancers chosen for functional validation in the current study were both associated with transcription factor genes previously implicated in controlling early blood and endothelial development. In view of this somewhat biased nature of choosing candidate elements for functional validation, further transgenic analyses of additional candidate enhancers will be required to assess the full potential of the current search parameters in identifying new enhancers active in developing blood and endothelial cells.
Pioneering studies in Drosophila suggest that further refinement of our computational approach will be possible (5-7). Accordingly, detailed structural and functional comparisons of the Fli-1 +12, PRH +1 and SCL +19 enhancers are likely to identify additional common features which could be incorporated into future algorithms. Moreover, identification of false positive binding site clusters (i.e. those lacking enhancer activity) will permit the inclusion of stringent negative criteria (24) .
Interestingly, deletion of the SCL +19 enhancer from the endogenous SCL locus in ES-cells appears to have little or no effect on the levels of SCL expression or the ability of ES cells to differentiate into blood cells either in vitro or in vivo (25) . This observation serves to underline the likely high degree of redundancy of mammalian regulatory elements, a point well illustrated by extensive deletion analyses of α and β globin regulatory elements (26) (27) (28) (29) . Dissection of transcription factor networks controlling development is currently most advanced in flies, worms and sea urchins. However, none of these three model organisms lend themselves to deleting specific enhancer sequences from the germline in order to study loss of function or possible redundancy of gene regulatory elements. Enhancer redundancy may therefore not be confined to vertebrates, and should be considered as a potential caveat whenever a given regulatory element is designated a network node connecting two transcription factors. Of note, redundancy of regulatory elements, and their subsequent partial specialization, likely represent important mechanisms by which organisms can evolve additional levels of biological complexity.
Two other recently described strategies promise to provide complementary approaches to genomewide identification of candidate cis-regulatory elements. Firstly, chromatin immunoprecipitation combined with genomic arrays should allow a description of transcription factor binding patterns within a given cell type (30, 31) . Secondly, genome-wide sampling of regions of open chromatin (32, 33) might provide a way of concentrating motif searches on the portion of the genome involved in regulating gene expression. However, both of these approaches require purification of significant numbers of cells, a particular problem when studying stem cell systems or early developmental programmes. Deciphering regulatory information encoded in the primary DNA sequence circumvents the need for pure cell populations and has the potential to provide information on cis-regulatory elements operating in all mammalian cell types regardless of the amount of biological material available. The approach used in the current study therefore represents a widely applicable strategy to characterise mammalian gene regulatory networks.
Materials and Methods

Identification of conserved binding site clusters
Genome-wide positions of consensus binding sites were identified in individual and aligned genomes available from Genome Bioinformatics at the University of California (Santa Cruz) using a program developed by our group called TFBSsearch, which examines a single sequence or global alignment for conserved non-overlapping binding sites (14) . Consensus sequences for the factors 
Functional analysis of candidate enhancers
Candidate enhancer sequences were amplified by PCR from human DNA and subcloned into the reporter plasmid pGl2-promoter (Promega). Cell lines were grown and transfected as described (13) . At least eight independent pools of stably transfected cells were assayed for each construct using a microplate luminometer as described previously (13) . Deletions in the Fli-1 and PRH enhancer constructs were generated by PCR and confirmed by sequencing. Chromatin immunoprecipitation assays were performed in the haematopoietic progenitor cell line 416B as described (13) . Primer sequences used to amplify the Fli-1 and PRH/Hex enhancers were Fli1E-FW TGTTCTGCCACAGGTAAAGGAA, Fli1E-Rev TATGTTTGCTCCCAACGATCC, PRHEFw GACCCTTTCCGTTCATACAGGA and PRHE-Rev AAGTCACATCCCACACAGAGGA.
Transgenic mice were generated using pronuclear injection into CBA 3 C57/Bl.6 fertilized mouse oocytes which were allowed to divide to two cells prior to implantation into the oviducts of pseudopregnant CD1 female mice. For analysis of embryonic enhancer activity, recipient females were sacrificed and embryos analyzed at E11.5 days of gestation (F0 analysis). Embryos were stained with X-gal for β-galactosidase activity as described (21) . For genotyping, DNA from yolk sac was prepared and tested for the presence of the lacZ transgene by PCR with an internal myogenin control. 
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